FloodLAMP Biotechnologies, PBC

FloodLAMP Biotechnologies, PBC is a Public Benefit Corporation founded in 2020 with the goal of enabling globally scalable mass disease screening, particularly for COVID-19 and beyond. The company's slogan, "Globally scalable mass disease screening, for COVID-19 and beyond," encapsulates its mission.

With a focus on the Health Care industry, FloodLAMP is committed to bringing to market a key capability that can help control the spread of COVID-19: affordable, distributed molecular testing. Recognizing the limitations within the molecular diagnostics industry and clinical lab business, the company has adopted a nontraditional approach, custom creating a program to enable this capability. Additionally, FloodLAMP has adopted an open source strategy with the potential to unlock molecular diagnostics as a global public health tool.

As of now, FloodLAMP Biotechnologies, PBC does not have a record of its last investment or investors. However, with its innovative approach to addressing a critical public health need, FloodLAMP's efforts present an intriguing opportunity for potential venture capital investment.

Overall, FloodLAMP Biotechnologies, PBC's commitment to leveraging molecular testing for disease screening on a global scale, combined with its unconventional strategy and open source approach, positions the company as a compelling player within the public health and biotechnology sectors, offering potential for significant impact and investment opportunities.